ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1612

Kidney Biopsy Chronicity Grading in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Casal Moura, Marta Isabel Rodrigues, Mayo Foundation for Medical Education and Research, Rochester, Minnesota, United States
  • Fervenza, Fernando C., Mayo Foundation for Medical Education and Research, Rochester, Minnesota, United States
  • Specks, Ulrich, Mayo Foundation for Medical Education and Research, Rochester, Minnesota, United States
  • Sethi, Sanjeev, Mayo Foundation for Medical Education and Research, Rochester, Minnesota, United States
Background

Kidney biopsy is valuable for prognostic assessment of renal outcomes in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) with glomerulonephritis (AAV-GN) but the impact of chronic changes is not determined.

Methods

A retrospective cohort study of MPO- or PR3-ANCA positive patients with AAV and active renal disease. We applied the Mayo Clinic Chronicity Score (MCCS), validated and evaluated its implications on outcome prediction in AAV-GN.

Results

We analyzed 329 patients with kidney biopsies available to score. The extent of chronicity was graded by MCCS as (i) minimal – 102 (31.0%), (ii) mild – 106 (32.2%), (iii) moderate – 86 (26.1%), and (iv) severe – 35 (10.6%). The MCCS grades correlated with the degree of renal function impairment at presentation (mean eGFR: 48.3 vs. 29.2 vs. 23.7 vs. 18.5 mL/min/1.73 m2, p<0.0001). Higher degrees of the individual components of the MCCS (glomerulosclerosis, interstitial fibrosis, tubular atrophy and arteriosclerosis) were associated with lower median eGFR (p<0.0001) and decreased event free (kidney failure (KF) and death) survival (p=0.002, p<0.0001, p<0.0001 and p=0.017, respectively). Patients with lower MCCS grades recovered renal function more frequently (p<0.0001). Increasing MCCS grades were associated with decreased renal recovery (p=0.001), more frequent events and shorter time to KF (p<0.0001), KF and death (p<0.0001), and death (p=0.042), independently of remission-induction treatment used (CYC or RTX). The MCCS stratified renal outcomes for each MCCS grade and can be used in clinical practice as a cut-off for KF prediction (MCCS≥4).

Conclusion

Chronic changes on kidney histology independently predict renal function, outcomes and response to treatment in AAV-GN.